On June 10, 2024, Amber Therapeutics, a UK-based medical technology company, successfully closed a Series A financing, raising $100 million (£80 million) from leading healthcare and technology investors in the U.S. and U.K. The round, one of the largest Series A financings in Europe for a medical technology company, was led by New Enterprise Associates and included new investors F-Prime Capital, Lightstone Ventures, and Intuitive Ventures, along with existing investors Oxford Science Enterprises and 8VC. Wilson Sonsini Goodrich & Rosati advised Amber on IP matters and U.S. corporate, tax, and CFIUS issues in the transaction.

Amber-UI is the first fully implantable adaptive neuromodulation therapy in clinical development for women with mixed urinary incontinence, targeting the pudendal nerve through a novel, minimally invasive surgical procedure. The proceeds of the financing will be used to fund the development of Amber-UI through pilot and pivotal studies toward regulatory approval in the U.S.

The Wilson Sonsini team that advised Amber on IP matters related to the transaction included Lou Lieto, Ellie Han, Michael Labriola, Stephen Heifetz, Michael Rizzuto, and Nick Upright. 

For more information, please see Amber's news release. Additional coverage can be found on Endpoints News.